EarningsQ2 2026 Earnings Report
MX:SYK Q2 2026 EPS Results
Actual EPS$66.69
Consensus EPS$63.04
Beat/MissBeat by +$3.65
One Year Ago EPS$56.57
MX:SYK Q2 2026 Revenue Results
Actual Revenue$119.09B
Expected Revenue$118.91B
Beat/MissBeat by +$174.66M
YoY Revenue Growth+9.42%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeAfter Close
Conference CallThursday, July 30, 2026
MX:SYK Upcoming Earnings
Stryker's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:SYK Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed broad recovery and operational momentum: solid organic growth (9%), a strong adjusted EPS beat (+17.9%), expanding margins, record Mako performance, multiple product launches and healthy cash generation/backlog. Key negatives were an acute supply disruption in peripheral vascular (Inari) that drove a U.S. vascular decline (‑6.7%), lingering costs and absorption effects from the prior cybersecurity incident, and some launch timing variability. Management expects backorders to be manageable by end of Q3 and reiterated confidence in the full‑year outlook and capital demand, so positives materially outweigh manageable near‑term headwinds.Company Guidance
Strong overall organic sales growth
Company delivered 9% organic sales growth in Q2 2026 (9% U.S., ~8.9% international). Management narrowed full‑year organic net sales guidance to 8.3%–9.3%.
Robust adjusted EPS and margin expansion
Adjusted EPS was $3.69, up 17.9% year‑over‑year. Adjusted gross margin improved to 66%, +60 basis points vs. prior year, and adjusted operating margin was 27.4% of sales, +170 basis points vs. prior year.
Capital demand, backlog and cash generation
Elevated backlog and strong capital orders (record month of Mako sales), year‑to‑date cash from operations of ~$1.8B, and cash & marketable securities of ~$3.5B. Management expects continued strength in hospital capital environment and resumed share repurchases (board previously approved ~$1B available).
Product innovation and commercial momentum
Best ever Q2 for Mako installations and rising utilization; full commercial launch of Mako RPS in the U.S.; Triathlon Gold and Triathlon Medial Stabilized Insert moving to full commercial launches; PROPHECY planning/guides approved for Encompass total ankle; Pangaea Trauma Plating System limited launch in Europe; Sonopet 3 planned—demonstrating steady cadence of new product introductions.
Segment-level strength across MedSurg, Endoscopy and Orthopedics
MedSurg & Neurotechnology organic growth of 9.2% (U.S. 8.9%, international 10.5%); Endoscopy U.S. organic +10.2%; Medical U.S. organic +13.1%; Orthopedics organic +8.6% (U.S. 9.1%, international 7.5%) with Trauma & Extremities U.S. +12.5% and Mako driving knee/OrthoTech momentum.
Strategic M&A and pipeline expansion
AVS acquisition closed this quarter (adds IVL capability); management expects potential above‑the‑knee IVL approval timing could allow sales before year‑end and continues to pursue M&A as primary capital deployment priority.
MX:SYK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed